SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Greed Is Good who wrote (226)2/6/1998 8:29:00 AM
From: Tom Genna   of 1510
 
The competition's timetable still falls behind IMNR slightly. Their drug may not necessarily supplant remune. One boosts immune components, other blocks entry into IMHO. For info the following is competition's news release :

<Picture>

<Picture: reuters>Immunex's Leukine drug may have HIV use
------------------------------------------------------------------------

SEATTLE, Feb 5 (Reuters) - Immunex Corp said Thursday
laboratory studies suggest its Leukine drug may have a role in
treating HIV patients by blocking the entry of the HIV virus
into human macrophages.
Macrophages are the immune system cells suspected of
harboring the last vestiges of HIV infection that remain after
years of drug cocktail therapy.
Leukine, which is being evaluated for use on HIV patients,
is already used to treat leukemia and other cancers by
stimulating the production of white blood cells.
Immunex said it presented its findings at the Fifth Annual
Retroviruses and Opportunistic Infections Conference in Chicago
earlier this week.
Immunex also presented positive findings of a safety trial
evaluating the use of Leukine in patients on stable
anti-retroviral therapy. The findings indicated that Leukine
did not increase viral load and may have contributed to a
reduction in viral load, it said. Viral load is an important
marker used by healthcare providers to monitor HIV disease
progression.
The company also said Leukine was associated with an
increase in the number of CD4+ T cells, which are progressively
depleted by HIV disease, in a significant number of treated
individuals.
"The laboratory data suggest that Leukine may be capable of
blocking and decreasing in number the co-receptors necessary
for HIV entry," said Mike Widmer, vice president of biological
sciences at Immunex.
"This effect could be responsible for both the reduction in
viral load and the increase in CD4+ T cells that was evident in
the clinical trial."
He said the company will continue laboratory and clinical
testing to determine if Leukine may have a therapeutic role in
treatment of early-stage HIV disease.
Immunex said its Phase I trial revealed that eight of the
10 patients receiving Leukine had an increase of 30 percent or
more in CD4+ T cells as compared with three of the 10 patients
receiving placebo.
Immunex said it has completed enrollment of a 300-patient,
Phase III trial evaluating Leukine in reducing the incidence of
infections and death among patients with AIDS. Results of the
trial are expected in early 1999.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News